TS1621628600	drug 4 38	monoamine oxidase type B inhibitor
TS1321628600	drug 39 49	rasagiline
TS221628600	drug 92 100	tyramine
TS2421628600	drug 115 125	Rasagiline
TS1921628600	drug 132 189	irreversible monoamine oxidase type B ( MAO-B ) inhibitor
TS1221628600	drug 325 333	levodopa
TS1121628600	drugEffect 350 398	inhibition of monoamine oxidase type A ( MAO-A )
TS1421628600	sideeffect 459 471	hypertensive
TS2321628600	drug 499 507	tyramine
TS621628600	drug 545 553	Tyramine
TS921628600	drug 600 610	rasagiline
TS721628600	sideeffect 648 668	tyramine sensitivity
TS1021628600	drug 688 698	rasagiline
TS821628600	sideeffect 798 818	tyramine sensitivity
TS421628600	drug 903 913	rasagiline
TS321628600	food 1010 1038	dietary tyramine restriction
TS2121628600	drug 1085 1095	rasagiline
TS121628600	food 0 1122	The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge ?
Rasagiline is an irreversible monoamine oxidase type B ( MAO-B ) inhibitor indicated for the treatment of the signs and symptoms of idiopathic Parkinson disease as initial monotherapy and as adjunct therapy to levodopa .
Pharmacologic inhibition of monoamine oxidase type A ( MAO-A ) , but not MAO-B , poses a risk of the " cheese effect , " a hypertensive response to excess dietary tyramine , a biogenic sympathomimetic amine .
Tyramine challenge studies , conducted to characterize rasagiline selectivity for the MAO-B enzyme and tyramine sensitivity , demonstrate that rasagiline , when used at the recommended dose , is selective for MAO-B and is not associated with heightened tyramine sensitivity .
This conclusion is also supported by safety results from large clinical trials of rasagiline in Parkinson disease involving 2066 rasagiline- rasagiline-treated patients who did not require dietary tyramine restriction per protocol .
In late 2009 , US labeling for rasagiline was modified to state that
TS2221628600	drug 1186 1196	rasagiline
TS2021628600	drug 1258 1268	rasagiline
TS1821628600	treatedDisease 1542 1558	pheochromocytoma
T1	treatedDisease 70 87	Parkinson disease
R1	treat Arg1:TS1321628600 Arg2:T1	
R2	treat Arg1:TS1621628600 Arg2:T1	
T2	treatedDisease 258 275	Parkinson disease
R3	treat Arg1:TS1921628600 Arg2:T2	
R4	treat Arg1:TS2421628600 Arg2:T2	
R5	treat Arg1:TS1221628600 Arg2:T2	
T3	sideeffect 439 452	cheese effect
R6	has_sideeffect Arg1:TS2321628600 Arg2:TS1421628600	
R7	has_sideeffect Arg1:TS2321628600 Arg2:T3	
T4	drug 512 542	biogenic sympathomimetic amine
T5	drugEffect 611 643	selectivity for the MAO-B enzyme
R8	has_effect Arg1:TS921628600 Arg2:T5	
R9	has_sideeffect Arg1:TS921628600 Arg2:TS721628600	
T6	treatedDisease 917 934	Parkinson disease
R10	treat Arg1:TS421628600 Arg2:T6	
R11	no_effect_on_drug Arg1:TS321628600 Arg2:TS421628600	
T7	food 1123 1152	dietary tyramine restrictions
T8	drugEffect 1297 1316	selective for MAO-B
R12	has_effect Arg1:TS2021628600 Arg2:T8	
T9	dosage 1341 1351	up to 1 mg
T10	drug 1406 1428	sympathomimetic amines
T11	drug 1438 1466	sympathomimetic vasopressors
T12	drug 1487 1494;1498 1514	general local anesthesia
R13	relation Arg1:T7 Arg2:TS2221628600	
